Ping Liang1, Karim Sallam2, Haodi Wu2, Yingxin Li2, Ilanit Itzhaki2, Priyanka Garg2, Ying Zhang2, Vittavat Vermglinchan2, Feng Lan2, Mingxia Gu2, Tingyu Gong3, Yan Zhuge2, Chunjiang He2, Antje D Ebert2, Veronica Sanchez-Freire2, Jared Churko2, Shijun Hu2, Arun Sharma2, Chi Keung Lam2, Melvin M Scheinman4, Donald M Bers5, Joseph C Wu6. 1. Stanford Cardiovascular Institute, Department of Medicine, Division of Cardiovascular Medicine, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California; The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Institute of Translational Medicine, Zhejiang University, Hangzhou, China. Electronic address: pingliang@zju.edu.cn. 2. Stanford Cardiovascular Institute, Department of Medicine, Division of Cardiovascular Medicine, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California. 3. Stanford Cardiovascular Institute, Department of Medicine, Division of Cardiovascular Medicine, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California; The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. 4. Department of Medicine, Division of Cardiology, University of California, San Francisco, California. 5. Department of Pharmacology, University of California, Davis, California. 6. Stanford Cardiovascular Institute, Department of Medicine, Division of Cardiovascular Medicine, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California. Electronic address: joewu@stanford.edu.
Abstract
BACKGROUND: Brugada syndrome (BrS), a disorder associated with characteristic electrocardiogram precordial ST-segment elevation, predisposes afflicted patients to ventricular fibrillation and sudden cardiac death. Despite marked achievements in outlining the organ level pathophysiology of the disorder, the understanding of human cellular phenotype has lagged due to a lack of adequate human cellular models of the disorder. OBJECTIVES: The objective of this study was to examine single cell mechanism of Brugada syndrome using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). METHODS: This study recruited 2 patients with type 1 BrS carrying 2 different sodium voltage-gated channel alpha subunit 5 variants as well as 2 healthy control subjects. We generated iPSCs from their skin fibroblasts by using integration-free Sendai virus. We used directed differentiation to create purified populations of iPSC-CMs. RESULTS: BrS iPSC-CMs showed reductions in inward sodium current density and reduced maximal upstroke velocity of action potential compared with healthy control iPSC-CMs. Furthermore, BrS iPSC-CMs demonstrated increased burden of triggered activity, abnormal calcium (Ca2+) transients, and beating interval variation. Correction of the causative variant by genome editing was performed, and resultant iPSC-CMs showed resolution of triggered activity and abnormal Ca2+ transients. Gene expression profiling of iPSC-CMs showed clustering of BrS compared with control subjects. Furthermore, BrS iPSC-CM gene expression correlated with gene expression from BrS human cardiac tissue gene expression. CONCLUSIONS: Patient-specific iPSC-CMs were able to recapitulate single-cell phenotype features of BrS, including blunted inward sodium current, increased triggered activity, and abnormal Ca2+ handling. This novel human cellular model creates future opportunities to further elucidate the cellular disease mechanism and identify novel therapeutic targets.
BACKGROUND:Brugada syndrome (BrS), a disorder associated with characteristic electrocardiogram precordial ST-segment elevation, predisposes afflicted patients to ventricular fibrillation and sudden cardiac death. Despite marked achievements in outlining the organ level pathophysiology of the disorder, the understanding of human cellular phenotype has lagged due to a lack of adequate human cellular models of the disorder. OBJECTIVES: The objective of this study was to examine single cell mechanism of Brugada syndrome using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). METHODS: This study recruited 2 patients with type 1 BrS carrying 2 different sodium voltage-gated channel alpha subunit 5 variants as well as 2 healthy control subjects. We generated iPSCs from their skin fibroblasts by using integration-free Sendai virus. We used directed differentiation to create purified populations of iPSC-CMs. RESULTS: BrS iPSC-CMs showed reductions in inward sodium current density and reduced maximal upstroke velocity of action potential compared with healthy control iPSC-CMs. Furthermore, BrS iPSC-CMs demonstrated increased burden of triggered activity, abnormal calcium (Ca2+) transients, and beating interval variation. Correction of the causative variant by genome editing was performed, and resultant iPSC-CMs showed resolution of triggered activity and abnormal Ca2+ transients. Gene expression profiling of iPSC-CMs showed clustering of BrS compared with control subjects. Furthermore, BrS iPSC-CM gene expression correlated with gene expression from BrS human cardiac tissue gene expression. CONCLUSIONS:Patient-specific iPSC-CMs were able to recapitulate single-cell phenotype features of BrS, including blunted inward sodium current, increased triggered activity, and abnormal Ca2+ handling. This novel human cellular model creates future opportunities to further elucidate the cellular disease mechanism and identify novel therapeutic targets.
Authors: Steven R Houser; Kenneth B Margulies; Anne M Murphy; Francis G Spinale; Gary S Francis; Sumanth D Prabhu; Howard A Rockman; David A Kass; Jeffery D Molkentin; Mark A Sussman; Walter J Koch; Walter Koch Journal: Circ Res Date: 2012-05-17 Impact factor: 17.367
Authors: Bas J Boukens; Marc Sylva; Corrie de Gier-de Vries; Carol Ann Remme; Connie R Bezzina; Vincent M Christoffels; Ruben Coronel Journal: Circ Res Date: 2013-05-09 Impact factor: 17.367
Authors: Angeliki Asimaki; Sudhir Kapoor; Eva Plovie; Anne Karin Arndt; Edward Adams; ZhenZhen Liu; Cynthia A James; Daniel P Judge; Hugh Calkins; Jared Churko; Joseph C Wu; Calum A MacRae; André G Kléber; Jeffrey E Saffitz Journal: Sci Transl Med Date: 2014-06-11 Impact factor: 17.956
Authors: Ning Sun; Masayuki Yazawa; Jianwei Liu; Leng Han; Veronica Sanchez-Freire; Oscar J Abilez; Enrique G Navarrete; Shijun Hu; Li Wang; Andrew Lee; Aleksandra Pavlovic; Shin Lin; Rui Chen; Roger J Hajjar; Michael P Snyder; Ricardo E Dolmetsch; Manish J Butte; Euan A Ashley; Michael T Longaker; Robert C Robbins; Joseph C Wu Journal: Sci Transl Med Date: 2012-04-18 Impact factor: 17.956
Authors: Maaike Hoekstra; Christine L Mummery; Arthur A M Wilde; Connie R Bezzina; Arie O Verkerk Journal: Front Physiol Date: 2012-08-31 Impact factor: 4.566
Authors: Priyanka Garg; Angelos Oikonomopoulos; Haodong Chen; Yingxin Li; Chi Keung Lam; Karim Sallam; Marco Perez; Robert L Lux; Michael C Sanguinetti; Joseph C Wu Journal: J Am Coll Cardiol Date: 2018-07-03 Impact factor: 24.094
Authors: Mu Chen; Dong-Zhu Xu; Adonis Z Wu; Shuai Guo; Juyi Wan; Dechun Yin; Shien-Fong Lin; Zhenhui Chen; Michael Rubart-von der Lohe; Thomas H Everett; Zhilin Qu; James N Weiss; Peng-Sheng Chen Journal: JCI Insight Date: 2018-11-15